| # | Form | Change | Current Location | Reason |
| 1 | Supporting Document A | Added bullet "A" to Background | Page 1 - 1st paragraph | to organize the Background section under bullet A |
| 2 | Supporting Document A | added "Calendar Year" | Page 1 - 1st paragraph | to define acronym CY |
| 3 | Supporting Document A | added "Hospital Outpatient Prospective Payment and Ambulatory Surgical Center | Page 1 - 1st paragraph | to define acronym OPPS/ASC |
| 4 | Supporting Document A | added "the Centers for Medicare & Medicaid Services" | Page 1 - 1st paragraph | to define acronym CMS |
| 5 | Supporting Document A | added "Health Resources & Services Administration" | Page 1 - 1st paragraph | to define acronym HRSA |
| 6 | Supporting Document A | deleted "Hospital Outpatient Prospective Payment System" | Page 1 - 2nd paragraph | reduntant with OPPS |
| 7 | Supporting Document A | deleted "certain" covered entity hospitals | Page 1 - 2nd paragraph | to clarify that it covers not certain but all covered entity hospitals |
| 8 | Supporting Document A | changed Justification Section to bullet B from A | Page 1 - 2nd section | to follow the bullet A for the next section. |
| 9 | Supporting Document A | replaced "used does" with "did" not fully.. | Page 2 - 3rd paragraph | to correct grammer and for clarity |
| 10 | Supporting Document A | deleted "Therefore, CMS did not use the GAO data, which did not take all of the discounts into consideration when conducting the survey.3" | Page 2 - 3rd paragraph | Not pertinent to the narrative |
| 11 | Supporting Document A | deleted footnote "3 https://www.govinfo.gov/content/pkg/FR-2005-11-10/pdf/05-22136.pdf" | Page 2 - footnote | since the sentence was deleted, the footnote is no longer needed |
| 12 | Supporting Document A | added "ceiling price" in "As noted previously, 340B entities receive these drugs at a discount and are charged a maximum price, ceiling price, for these drugs because of their participation. | Page 2 -3. | added for clarity |
| 13 | Supporting Document A | deleted "also" in We also note that these covered entities also have access to.. | Page 3 - top paragraph, 2nd sentence | deleted for clarity |
| 14 | Supporting Document A | replaced "Health Resources and Services Administration’s" with HRSA's | Page 3 - 2nd paragraph | to use the acronym HRSA |
| 15 | Supporting Document A | deleted "Average Sale Price" and "plus" | Page 3 - 2nd paragraph | to use acronym ASP and the commonly accepted "ASP+6" language |
| 16 | Supporting Document A | added "340B" ceiling price | Page 4 - top paragraph | to clarify that we are referring to the 340B ceiling price |
| 17 | Supporting Document A | added "either of" | Page 4 - 2nd paragraph | to clarify that we are referring to either of quarters |
| 18 | Supporting Document A | replaced "In addition, we are only asking for data on the acquisition price for two quarters for separately payable drugs identified in Addendum B on the CMS Website." with "In addition, we are only asking for data on the acquisition price at the hospital level for two quarters. We are requesting for the separately payable drugs identified in Addendum B on the CMS Website." | Page 4 - 3rd paragraph | to provide clarity that CMS is only requesting information at the hospital level, not at the Provider Based Department level that we had initially proposed. |
| 19 | Supporting Document A | Substituted "The practical utility of the 340B drug acquisition cost survey is that CMS is exercising the explicit statutory authority to obtain drug acquisition cost per section 1833(t)(14)(D) and the agency may use the information collected to set payment rates for drugs purchased under the 340B Program." for "This is a new collection and the agency may use the information collected to set payment rates for drugs purchased under the 340B Program." |
Page 4 - under bullet 2. Information Users | to discuss the practical utility per the public comments received that CMS did not discuss a practical utility for the survey. |
| 20 | Supporting Document A | replaced "However, often time" with "Often time, however," | Page 5 - "Duplication of efforts" | edited to correct sentence flow |
| 21 | Supporting Document A | inserted 84 FR 51590 | Page 5 - "Federal Register/Outside Consulation" | inserted since it was TBD |
| 22 | Supporting Document A | CMS provided responses to the public comments from the 60-day Federal Register notice on the 340B drug acquisition survey. | Page 5 - "Federal Register/Outside Consulation" | inserted to notify the CMS responses to the public comments from the 60-day Federal Register notice |
| 23 | Supporting Document A | replaced "assuming" with "we assumed" | Page 6 - Burden Estimates (Hours & Wages) | edited for grammatical correction |
| 24 | Supporting Document A | inserted "such" as postage or copying | Page 6 - Burden Estimates (Hours & Wages) | inserted for clarity |
| 25 | Supporting Document A | substituted "analysts" for "analyses" | Page 6 - Cost to Federal Government | corrected for clarity |
| 26 | Supporting Document A | inserted "we" and "figure" in "we used this figure to derive the following estimate" | Page 6 - Burden Estimates (Hours & Wages) | inserted for clarity |
| 27 | Supporting Document A | moved last paragraph from the background section into section 2 | Page 5 - Information Users | inserted paragraph for clarity |
| 28 | Supporting Document A | deleted "in part" | Page 2 - Need and Legal Basis | deleted for clarity |
| 29 | Supporting Document A | inserted "the" | Page 3 - Need and Legal Basis | inserted for clarity |
| 30 | Supporting Document A | substituted "via" for "in response to" | Page 4 - Need and Legal Basis | corrected for clarity |
| 31 | Supporting Document A | inserted "or" | Page 4 - Need and Legal Basis | inserted for clarity |
| 32 | Supporting Document A | deleted underline from "See" | Page 4 - Need and Legal Basis | deleted for clarity |
| 33 | Supporting Document A | deleted "for" | Page 4 - Need and Legal Basis | deleted for clarity |
| 34 | Supporting Document A | inserted "or where a hospital does not respond to the survey" | Page 4 - Need and Legal Basis | inserted for clarity |
| 35 | Supporting Document A | deleted "include" inserted "use" | Page 4 - Need and Legal Basis | corrected for clarity |
| 36 | Supporting Document A | deleted "are shared" | Page 5 - Duplication of efforts | deleted for clarity |
| 37 | Supporting Document A | deleted "privacy" inserted "confidentiality" | Page 6 - Confidentiality | corrected for clarity |
| 38 | Supporting Document A | deleted "provided" inserted "required" | Page 6 - Confidentiality | corrected for clarity |
| 39 | Supporting Document A | deleted "privacy" inserted "confidentiality" | Page 6 - Sensitive Questions | corrected for clarity |
| 40 | Supporting Document A | deleted "provided" inserted "required" | Page 6 - Sensitive Questions | corrected for clarity |
| 41 | Supporting Document A | deleted page break | Page 8 - Cost to Federal Government | corrected for clarity |
| 42 | Supporting Document A | replaced "This is a new collection of information." with "None. While CMS is revising the 340B drug acquisition cost survey to eliminate the request for information at the hospital off-campus provider-based department (PBD), to instead permit hospitals to respond at the hospital level, we are not changing the original burden estimate because commenters suggested that our estimate was too low. We believe that this change will ease the burden that concerned many commenters while allowing CMS to capture the appropriate data for future use and is more consistent with the original burden we estimated for the survey." | Page 8 - Changes to Burden | edited to reflect the change in elminating PBD collection to ease the burden that is more consistent with the burden estimate. |
| # | Form | Change | Current Location | Reason |
| 1 | Supporting Document B | changed to "CMS contractors will make survey information available to all hospitals that purchase drugs through the 340B Program." from "CMS shall disseminate (via the Medicare Administrative Contractors (MACs)) the survey to all hospitals paid under the OPPS that purchase drugs through the 340B Program." | Page 1 - 2nd paragraph | changed to clarify the method of making the survey available to respondents and that the respondents are not limited to OPPS. |
| 2 | Supporting Document B | changed to "1,384 responses" from "1,338 responses" | Page 1 - 2nd paragraph | updated database indicate updated numbers. |
| 3 | Supporting Document B | changed to "Each hospital that acquired drugs under the 340B program in the fourth quarter of 2018 and/or first quarter of 2019 is required to complete one survey that includes acquisition costs for each of the two quarters." from "Each hospital is required to complete one survey that includes acquisition costs for each SCOD for two quarters (Quarter 4 of 2018 and Quarter 1 of 2019)." | Page 1 - 2nd paragraph | to clarify and refine the sentence for better flow |
| 4 | Supporting Document B | deleted "the authority" Section 1833.. | Page 1 - 2nd paragraph | deleted since it is implied |
| 5 | Supporting Document B | added "which" and deleted "part" | Page 1 - 2nd paragraph | corrected typo error from earlier version |
| 6 | Supporting Document B | added "CMS is surveying the complete universe of 340B covered hospitals for the survey period" and deleted "NA" | Page 1 - bullet 2 | to clarify that this suvey represent the universe of the study subject so there is no need for statistical validity |
| 7 | Supporting Document B | substituted "CMS contractors will make available notice of the surveys and receive the survey responses." for "the MACs shall disseminate and receive the survey data. The MACs shall follow up with each hospital that has not responded to the survey or sent in incomplete data approximately two weeks after survey is distributed." | Page 1 - bullet 3 | changed to clarify the method of making the survey available to respondents |
| 8 | Supporting Document B | corrected "price" to "prices" | Page 1 - bullet 3 | plurality correction |
| 9 | Supporting Document B | substituted "rate" for "amount" | Page 2 - top | changed to correct meaning |
| 10 | Supporting Document B | substituted "Not applicable since CMS is not using a sampling methodology." for "CMS shall not undertake any methods or tests of procedures." | Page 1 - bullet 4 | reworded for clarity |
| 11 | Supporting Document B | inserted "the" | Page 1 - bullet 1 | inserted for clarity |
| 12 | Supporting Document B | deleted "make available notice" inserted "announce the availability" | Page 1 - bullet 3 | reworded for clarity |
| 13 | Supporting Document B | inserted "CMS will also uses 340B ceiling prices as proxies for the acquisition costs of drugs where a hospital fails to respond to the survey." | Page 1 - bullet 4 | reworded for clarity |
| # | Form | Change | Current Location | Reason |
| 1 | Instruction Sheet | changed "Collection Period" to "Survey Response Period" | Page 1 - top | change to provide clarity |
| 2 | Instruction Sheet | changed from "February 23, 2020 to March 6, 2020" to "March 23, 2020 to April 10, 2020" | Page 1 - top under Survey Response Period | timeline has changed |
| 3 | Instruction Sheet | deleted "under the hospital outpatient prospective payment system" | Page 1 - 1st paragraph under WHO SHOULD FILL OUT THIS FORM | deleted to be consistent across the supporting documents |
| 4 | Instruction Sheet | added new section "WHAT INFORMATION IS REQUIRED? For each applicable hospital, the survey shall reflect the net acquisition cost for each SCOD acquired under the 340B program, (that is, the sub-ceiling price after all applicable discounts/rebates). The acquisition cost should be reported regardless of whether or not the drug was dispensed or whether the drug was dispensed in multiple settings and regardless of how it was purchased (such as in a replenishment model under the 340B program). We are only requesting the acquisition cost of the drugs under the 340B program during the specified timeframe listed below. Drugs acquired outside of the 340B program should not be included on the survey." | Page 1 - new section | to provide further clarification on 340B acquisition cost of drugs per public comments |
| 5 | Instruction Sheet | added "Please fill out the attached Excel spreadsheet. In the spreadsheet tab "Hospital Information," please provide the following information:" | Page 1 - bottom | to provide specific Hospital information on a specific tab on the spreadsheet |
| 6 | Instruction Sheet | inserted "CONFIDENTIALITY CMS pledges to maintain confidentiality of individual responses that include acquisition prices for each SCOD to the extent provided by law. However, CMS may make public average acquisition prices reported for each SCOD. To the extent that acquisition prices for certain SCODs are deemed sensitive and/or confidential, we do not intend to make such prices available in an individually identifiable manner. As noted in section 10 above, we pledge privacy to the extent provided by law." |
Page 1 - below what information is required | added to provide respondents on the confidentiality of the data |
| 7 | Instruction Sheet | inserted "The survey is an Excel spreadsheet that will be available for download from each Medicare Administrative Contractor (MAC) website(s) that are listed at the end of the Instruction Sheet." | Page 2 - top of page | added to provide additional instructions on spreadseet |
| 8 | added "In the spreadsheet tab "Hospital Information," please provide the following information:" | added to provide point to Hospital Information tab | ||
| 9 | Instruction Sheet | inserted Contact "Name" | Page 2 - top | to clarify we are asking for contact name |
| 10 | Instruction Sheet | inserted "Hospital Address, Email, Phone Number" | Page 2 - under Hospital Information section | added to include contact person and email, phone to reach the POC for the respondent hospital |
| 11 | Instruction Sheet | substituted "Please complete the Excel spreadsheet. In the spreadsheet tab entitled "Survey", please provide the following information:" for "Please fill out the attached Excel spreadsheet. In this spreadsheet, please provide the following information:" | Page 2 - top | rewrote passage to clarify for "Survey" tab |
| 12 | Instruction Sheet | deleted "2. Provider Based Department Name List each provider based department of the hospital that is enrolled in the 340B program and is paid under the Medicare Hospital Outpatient Prospective Payment System (OPPS). For example, oncology department A, oncology department B." | Page 2 - top | deleted per the public comment that this would be too burdensome to collect information at the PBD level |
| 13 | Instruction Sheet | Renumbered HCPCS code for each Drug to 2. | ||
| 14 | Instruction Sheet | replaced "For each SCOD identified with status indicator “K” or “G”, list the healthcare common procedure coding system code (HCPCS). For example “J1234.” with "a. For each SCOD HCPCS code associated with status indicator “K” or “G,” list the healthcare common procedure coding system code (HCPCS). • Examples: • “J0885” represents epoetin alfa. • "J0878" represents daptomycin." |
Page 2 under HCPCS code for each Drug | edited to provide clarification |
| 15 | Instruction Sheet | Inserted "a. Exclusions: Please exclude vaccines, skin substitutes with a status indicator (SI) "K" or "G" from the survey responses." | Page 2 under HCPCS code for each Drug, b. | added to provide clarification on drugs excluded on the survey |
| 16 | Instruction Sheet | re-ordered the bullets "c" "d" bullets under the HCPCS code for each Drug | under the HCPCS code for each Drug | re-ordered the bullets since we added the new bullet b on exclusions |
| 17 | Instruction Sheet | Tip: To narrow the selection, filter Addendum B, column C “SI”, for “K” and “G” only. This will help narrow the search. | Page 2 under HCPCS code for each Drug: | added to provide a tip on narrowing the data |
| 18 | Instruction Sheet | re-ordered the bullet 3 for Drug Name/Short Descriptor | bottom of page 2 | reorganized the bullets since we deleted PBD from earlier version |
| 19 | Instruction Sheet | replace name with Short Descriptor | Page 2 under Drug Name/ Short Descriptor: bullet a. | edited to clarify it's the short descriptor of the drug |
| 20 | Instruction Sheet | deleted "Enter National Drug Code (NDC)." | Page 2 under Drug Name/ Short Descriptor: | moved NDC to a new section below bullet 4. Dose |
| 21 | Instruction Sheet | added "The short descriptor for each SCOD is located in the column entitled “Short Descriptor” in Addendum B." under bullet a | Page 2 under Drug Name/ Short Descriptor. | added to provide further clarity |
| 22 | Instruction Sheet | added "Tip: Copy the short descriptor in Column B of Addendum B and paste into column C of the drug survey." | Page 2 under Drug Name/ Short Descriptor: below bullet a. | provided tip for respondents using addendum B |
| 23 | Instruction Sheet | re-ordered Dose under bullet 4. | Page 3 under Dose | reorganized the bullets since we deleted PBD section from earlier version |
| 24 | Instruction Sheet | added "HCPCS dose" in Dose | Page 3, bullet 4, Dose (as reflected in HCPCS dose descriptor) | added for clarification |
| 25 | Instruction Sheet | substituted "a. This is the amount of drug to which the acquisition cost corresponds. List the HCPCS dosage for each drug as reflected in the HCPCS long descriptor or the “HCPCS Dosage” identified in the crosswalk files discussed below. For example, the amount of drug used for reporting J0885, epoetin alfa, is 1,000 units." for "List the dosage unit for each drug as reflected in the HCPCS descriptor. For example 1mg or 1 vial." | Page 3, bullet a under Dose | provided clarifying instructions |
| 26 | Instruction Sheet | added "5. NDC (National Drug Code)—Optional. a. You may choose to include the National Drug Code (NDC), but doing so is optional. Your organization may have multiple NDCs for each HCPCS code depending on your acquisition. Please note that CMS publishes quarterly NDC-HCPCS Crosswalk files that are available on the CMS website. Due to an operational lag time that exist between the manufacturers' reporting of the NDCs/ASPs and their CMS publication, the October 2018 HCPCS codes do not correspond to the October 2018 ASP NDC-HCPCS Crosswalk. • For HCPCS codes listed in the October 2018 Addendum B, corresponding NDC crosswalk files appear under the April 2019 ASP NDC-HCPCS Crosswalk. • For HCPCS codes listed in the January 2019 Addendum B, corresponding NDC crosswalk files appear under the July 2019 ASP NDC-HCPCS Crosswalk. • The April 2019 and July 2019 Crosswalks appear in the Related links section for the following CMS webpage: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2019ASPFiles." b. The April 2019 and July 2019 crosswalk files each contain 10 files. Combining the following three files from each quarter’s will create a list of NDCs associated with the majority of HCPCS codes that are billed under OPPS: • AWP NDC-HCPCS Crosswalk • ASP NDC-HCPCS Crosswalk • OPPS NDC-HCPCS Crosswalk Please note that although the NDC-HCPCS crosswalk files provide examples of commonly associated NDCs for the majority of the HCPCS codes, these files do not provide a complete and comprehensive list of all available NDCs for each HCPCS code. Thus, respondents may include acquisition costs for additional NDCs associated to a given HCPCS code. c. Please be sure to utilize the most recent versions of the crosswalk files in the hyperlinks above. Some of the crosswalk files have been updated very recently." |
bullet 5. NDC | added NDC section that provides information on HCPCS-NDC crosswalks in response to public comments. The hyperlinks point directly to the updated files on CMS.gov |
| 27 | Instruction Sheet | added "6. Q4 2018 Payment Rate a. The payment rate may be obtained from the OPPS Addendum B for Q4 2018" |
bullet 6. | this column was there on the survey spreadsheet previously but was left out as an error from the previous version. |
| 28 | Instruction Sheet | added "7. Q1 2019 Payment Rate a. The payment rate may be obtained from the OPPS Addendum B for Q1 2019" |
bullet 7. | this column was there on the survey spreadsheet previously but was left out as an error from the previous version. |
| 29 | Instruction Sheet | re-ordered the bullet 8. | bullet 8. | re-ordered since additions were added as discussed above |
| 30 | Instruction Sheet | added "under the 340B program" following For each SCOD purchased | under bullet 8. Average 340B Price of Drug for Q4 of CY 2018 (October 1, 2018-December 31, 2018), bullet a. | to provide more clarification that is intended to be for the 340B program only |
| 31 | Instruction Sheet | substituted "4th" for "last" quarter | under bullet 8. Average 340B Price of Drug for Q4 of CY 2018 (October 1, 2018-December 31, 2018), bullet a. | to provide more clarification it is the 4th quarter of 2018 |
| 32 | Instruction Sheet | added "based on the cost report on the amount of drug in a single billing unit of the corresponding HCPCS billing code. • The amount of drug represented by a single billing unit of a HCPCS code, also referred to as the HCPCS code dosage, can be found in the “HCPCS Dosage” column of the NDC-HCPCS Crosswalk files mentioned above." |
under bullet 8. Average 340B Price of Drug for Q4 of CY 2018 (October 1, 2018-December 31, 2018), bullet a. | to provide clarification on a single billing unit for 2018 |
| 33 | Instruction Sheet | re-ordered the bullet 9. | bullet 9. | re-ordered since additions were added as discussed above |
| 34 | Instruction Sheet | added "under the 340B program" following For each SCOD purchased | under bullet 9. Average 340B Price of Drug for Q1 of CY 2019 (January 1, 2019-March 31, 2019), bullet a. | to provide more clarification that is intended to be for the 340B program only |
| 35 | Instruction Sheet | added "based on the cost report on the amount of drug in a single billing unit of the corresponding HCPCS billing code. • The amount of drug represented by a single billing unit of a HCPCS code, also referred to as the HCPCS code dosage, can be found in the “HCPCS Dosage” column of the NDC-HCPCS Crosswalk files mentioned above." |
under bullet 9. Average 340B Price of Drug for Q1 of CY 2019 (January 1, 2019-March 31, 2019), bullet a. | to provide clarification on a single billing unit for 2019 |
| 36 | Instruction Sheet | substituted "Completed surveys should be submitted to your MAC no later than Monday, April 10, 2020." for "Completed surveys should be submitted to your Medicare Administrative Contractor no later than Monday, March 16, 2020." | bottom of page 4. | rewording and timeline changed |
| 37 | Instruction Sheet | added "Calculation Examples 1. HCPCS code J0885 (Injection, epoetin alfa, (for non-esrd use), 1000 units) include products sold under the brand names Epogen and Procrit. The drug products are sold in a variety of amounts, including vials and syringes that contain between 2000 units and 40,000 units of epoetin packaged in amounts that vary from 4 to 25 vials. On the CMS NDC-HCPCS Crosswalk files, the "HCPCS Dosage" column indicates that CMS payment of J0885 to outpatient hospitals (and other providers billing Part B by HCPCS codes) is based on 1,000 units of epoetin. For the survey, CMS is seeking the 340B average acquisition cost of J0885 per 1,000 units. Therefore, if the acquisition cost of a package of ten 20,000 unit epoetin vials is $1800, the acquisition cost of each 20,000 unit epoetin vial in the 10 vial package is $180. For reporting, the acquisition cost per 1,000 units of epoetin (corresponding to the amount in the HCPCS dosage as well as the HCPCS code dose descriptor) would be $180 divided by 20, or $9.00. 2. HCPCS code J0878 (Injection, daptomycin, 1mg). Daptomycin is commonly sold in 350 mg or 500 mg vials packed in quantities ranging from 1 to 10 vials. The survey is seeking the acquisition cost of daptomycin based on 1 mg of the drug. If a package of ten 350 mg vial is acquired for $1400, then the acquisition cost a single 350 mg vial from the package is $140. The acquisition cost per 1 mg of daptomycin in the HCPCS dosage or dose descriptor, 1 mg, is $0.40." |
Page 5 | added to provide examples on calculating cost of HCPCS dosage |
| 38 | Instruction Sheet | added "Medicare Administrative Contractor (MAC) websites A/B MAC Jurisdiction Website: 1. Jurisdiction 5 Wisconsin Physicians Service Government Health Administrators https://www.wpsgha.com/wps/portal/mac/site/home/ 2. Jurisdiction 6 National Government Services, Inc. https://www.ngsmedicare.com/ngs/portal/ngsmedicare/newngs/entry/ 3. Jurisdiction 8 Wisconsin Physicians Service Government Health Administrators https://www.wpsgha.com/wps/portal/mac/site/home/ 4. Jurisdiction 15 CGS Administrators, LLC https://cgsmedicare.com/ 5. Jurisdiction E Noridian Healthcare Solutions, LLC, https://med.noridianmedicare.com/ 6. Jurisdiction F Noridian Healthcare Solutions, LLC https://med.noridianmedicare.com/ 7. Jurisdiction H Novitas Solutions, Inc. https://www.novitas-solutions.com/webcenter/portal/NovitasSolutions?_adf.ctrl-state=8qipjgz81_54 8. Jurisdiction J Palmetto GBA, LLC https://palmettogba.com/ 9. Jurisdiction K (National Government Services, Inc.) https://www.ngsmedicare.com/ngs/portal/ngsmedicare/newngs/entry/ 10. Jurisdiction L Novitas Solutions, Inc. https://www.novitas-solutions.com/webcenter/portal/NovitasSolutions?_adf.ctrl-state=8qipjgz81_4 11. Jurisdiction M Palmetto GBA, LLC https://palmettogba.com/ 12. Jurisdiction N First Coast Service Options, Inc. https://www.fcso.com/" |
page 6-7 | added to provide survey information on where the survey spreadsheet will be available |
| 39 | Instruction Sheet | deleted "or submit an email to [email protected]." | top of page 8 | changed contact since MAC will be the primary contact to respondents. |
| 40 | Instruction Sheet | substituted "Medicare Administrative Contractor" for "Gil Ngan at 410-786-8947." | under the PRA disclosure statement | changed contact since MAC will be the primary contact to respondents. |
| 41 | Instruction Sheet | deleted "drug pricing" | top of page 1 | deleted for clarity |
| 42 | Instruction Sheet | inserted "at all" | Page 1: WHAT INFORMATION IS REQUIRED? | inserted for clarity |
| 43 | Instruction Sheet | inserted "acquired" | Page 1: WHAT INFORMATION IS REQUIRED? | inserted for clarity |
| 44 | Instruction Sheet | deleted "as noted in section 10 we pledge confidentiality to the extent required by law | Page 1: Confidentiality | deleted for clarity |
| 45 | Instruction Sheet | deleted "are" and inserted "is" | Page 1: Confidentiality | corrected for clarity |
| 46 | Instruction Sheet | deleted "based on the cost report on the amount of drug" insert "for the amount corresponding" | Page 3: 8. Average 340B Price of Drug for Q4 of CY 2018 (October 1, 2018-December 31, 2018) | corrected for clarity |
| 47 | Instruction Sheet | deleted "based on the cost report on the amount of drug" insert "for the amount corresponding" | Page 3: 9. 9. Average 340B Price of Drug for Q1 of CY 2019 (January 1, 2019- March 31, 2019) | corrected for clarity |
| # | Form | Change | Current Location | Reason |
| 1 | Drug Survey Spreadsheet | added new tab "Hospital Information" that has 7 columns for respondents to provide their hospital information: Hospital Name, CCN (Medicare Provider Number), Contact Name, Contact Title, Hospital Address, Email, Phone Number | 2nd tab "Hospital Information" on Drug Survey Spreadsheet | This information is need if we need the MAC to follow up with questions on the respondent. |
| 2 | Drug Survey Spreadsheet | deleted "Provider Based Department Name" | Survey tab | CMS removed the reporting for Provider Based Department in response to public comments on burden |
| 3 | Drug Survey Spreadsheet | substituted "Drug Name/Short Descriptor" for "Drug Name/ Descriptor" | Survey tab, column C | edited to clarify it's the short descriptor of the drug |
| 4 | Drug Survey Spreadsheet | substituted "Dose (as reflected in HCPCS code descriptor)" for "Dose (as reflected in descriptor)" | Survey tab, column D | edited to clarify in the HCPCS code descriptor |
| 5 | Drug Survey Spreadsheet | added new NDC (11 digit) Optional column | Survey tab, column E | added to assist respondents and it is optional |
| 6 | Drug Survey Spreadsheet | replaced examples with 3 rows of HCPCS with real life examples | Survey tab, row 2-4 | edited to help respondents understand the requested information and that there may be multiple NDCs for every HCPCS |
| File Type | application/vnd.openxmlformats-officedocument.spreadsheetml.sheet |
| File Modified | 0000-00-00 |
| File Created | 0000-00-00 |